PL2986280T3 - Preparat kolchicyny w postaci o przedłużonym uwalnianiu i metody tworzenia takiego samego - Google Patents

Preparat kolchicyny w postaci o przedłużonym uwalnianiu i metody tworzenia takiego samego

Info

Publication number
PL2986280T3
PL2986280T3 PL14755124T PL14755124T PL2986280T3 PL 2986280 T3 PL2986280 T3 PL 2986280T3 PL 14755124 T PL14755124 T PL 14755124T PL 14755124 T PL14755124 T PL 14755124T PL 2986280 T3 PL2986280 T3 PL 2986280T3
Authority
PL
Poland
Prior art keywords
colchicine
sustained
creating
preparation
same
Prior art date
Application number
PL14755124T
Other languages
English (en)
Inventor
Susanne RIEL
Original Assignee
Murray & Poole Enterprises, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Murray & Poole Enterprises, Ltd. filed Critical Murray & Poole Enterprises, Ltd.
Publication of PL2986280T3 publication Critical patent/PL2986280T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL14755124T 2013-04-16 2014-04-16 Preparat kolchicyny w postaci o przedłużonym uwalnianiu i metody tworzenia takiego samego PL2986280T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361812514P 2013-04-16 2013-04-16
EP13194505 2013-11-26
EP14755124.6A EP2986280B1 (en) 2013-04-16 2014-04-16 Sustained-release formulations of colchicine and methods of using same
PCT/IB2014/001201 WO2014170755A2 (en) 2013-04-16 2014-04-16 Sustained-release formulations of colchicine and methods of using same

Publications (1)

Publication Number Publication Date
PL2986280T3 true PL2986280T3 (pl) 2021-10-25

Family

ID=49683519

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14755124T PL2986280T3 (pl) 2013-04-16 2014-04-16 Preparat kolchicyny w postaci o przedłużonym uwalnianiu i metody tworzenia takiego samego

Country Status (19)

Country Link
US (6) US20160081936A1 (pl)
EP (1) EP2986280B1 (pl)
JP (1) JP6480420B2 (pl)
KR (1) KR102271048B1 (pl)
CN (1) CN105307643A (pl)
AU (4) AU2014255434B2 (pl)
BR (1) BR112015026418B1 (pl)
CA (2) CA2909370A1 (pl)
CL (1) CL2015003072A1 (pl)
EA (1) EA037375B1 (pl)
MA (1) MA38576B2 (pl)
MX (2) MX377426B (pl)
MY (2) MY198452A (pl)
PL (1) PL2986280T3 (pl)
PT (1) PT2986280T (pl)
SG (1) SG11201508571WA (pl)
SI (1) SI2986280T1 (pl)
WO (1) WO2014170755A2 (pl)
ZA (1) ZA201507723B (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA032515B1 (ru) 2012-11-02 2019-06-28 Марри Энд Пул Энтерпрайзес, Лтд. Лечение или профилактика сердечно-сосудистых явлений с использованием колхицина
US20160081936A1 (en) 2013-04-16 2016-03-24 Murray And Poole Enterprises Limited Sustained-release formulations of colchicine and methods of using same
HUE054663T2 (hu) * 2013-04-16 2021-09-28 Murray & Poole Entpr Ltd A kolicicin tartós kibocsátási készítményei és az annak alkalmazás módszerei
JP2018516274A (ja) * 2015-04-17 2018-06-21 ムレイ アンド プール エンタープライズ リミテッド コルヒチンサリチル酸塩およびこの利用
US9907751B2 (en) * 2016-03-10 2018-03-06 RxOMEG Therapeutics LLC Composition and method of use of colchicine oral liquid
CA3068088C (en) * 2017-06-23 2024-01-23 Medcan Pharma A/S Cannabinoid pouch
US10226423B1 (en) 2017-12-20 2019-03-12 RxOMEG Therapeutics LLC Colchicine drug-to-drug interactions
WO2019149884A1 (en) 2018-02-02 2019-08-08 Murray & Poole Enterprises, Ltd Use of colchicine to inhibit tumor growth and metastases
CN110448527B (zh) * 2019-09-23 2021-11-26 杭州百诚医药科技股份有限公司 一种秋水仙碱口服溶液及其处方组成
GB201913827D0 (en) * 2019-09-25 2019-11-06 Cape Peninsula Univ Of Technology Sustained Release Formulation Containing Aspalathus linearis Extract
KR102112456B1 (ko) 2019-11-13 2020-05-19 주식회사 에이스바이오메드 간 질환 치료용 또는 치료 효과 증진을 위한 콜히친 복합제제
US12514832B2 (en) 2019-11-15 2026-01-06 Institut De Cardiologie De Montreal Methods for using low-dose colchicine after myocardial infarction
CN111150702B (zh) * 2019-12-04 2021-06-22 复旦大学 一种凝胶药物缓释制剂及其制备方法与应用
KR102584738B1 (ko) 2020-01-17 2023-10-06 한국생명공학연구원 콜히친을 포함하는 피부 질환 치료용 조성물
KR102150821B1 (ko) 2020-01-22 2020-09-03 주식회사 에이스바이오메드 간 질환 치료용 또는 치료 효과 증진을 위한 콜히친 복합제제
KR20210095249A (ko) 2020-01-22 2021-08-02 주식회사 에이스바이오메드 간 질환 치료용 또는 치료 효과 증진을 위한 콜히친 복합제제
KR102177781B1 (ko) 2020-04-27 2020-11-12 주식회사 에이스바이오메드 간 질환 치료용 또는 치료 효과 증진을 위한 콜히친, 우르소데옥시콜산 및 비페닐디메틸디카르복실레이트의 복합제제
WO2022132786A1 (en) * 2020-12-15 2022-06-23 Romeg Therapeutics Llc Methods and compositions for treating pericarditis
CN113476603B (zh) * 2021-07-08 2022-05-20 中南大学 一种红细胞膜包裹的磁性纳米颗粒及其制备方法和应用
CN118717741A (zh) * 2024-01-15 2024-10-01 华中科技大学同济医学院附属协和医院 秋水仙碱在制备用于增加冠状动脉斑块纤维帽厚度药物中的应用
KR102870211B1 (ko) * 2024-06-11 2025-10-16 (주)알피바이오 지속성 제제 조성물
CN121265579A (zh) * 2025-12-11 2026-01-06 华中科技大学同济医学院附属协和医院 秋水仙碱在制备tbk1磷酸化促进剂中的应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3546142A (en) 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
SE9003904D0 (sv) * 1990-12-07 1990-12-07 Astra Ab Method for the manufacture of a pharmaceutical dosage form
US5171217A (en) 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
US7820383B2 (en) 1997-03-10 2010-10-26 Interleukin Genetics, Inc. Method for diagnosing myocardial infarction
JP2000034224A (ja) * 1998-05-11 2000-02-02 Freunt Ind Co Ltd 徐放性錠剤、その添加剤組成物及びそれらの製造方法
US20020169145A1 (en) * 1998-10-14 2002-11-14 Rajen Shah Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
CN1434713A (zh) * 1999-12-22 2003-08-06 法马西亚公司 环加氧酶－2抑制剂的缓释制剂
NZ527832A (en) 2001-03-13 2006-03-31 Penwest Pharmaceuticals Co Chronotherapeutic dosage forms
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US20030144203A1 (en) 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
WO2006063091A2 (en) 2004-12-06 2006-06-15 Ronald Freudenberger Use of oxypurinol as an inhibitor of anti-neoplastic agent-induced cardiotoxicity
US20060171948A1 (en) 2005-02-02 2006-08-03 Weinstein Steven P Methods of using IL-1 antagonists to reduce C-reactive protein
US20060286108A1 (en) 2005-06-16 2006-12-21 Bell Katherine A Topical compositions for the treatment of chronic wounds
CN1748671A (zh) 2005-08-30 2006-03-22 孔庆忠 含抗有丝分裂药物的缓释注射剂
CN1939290A (zh) 2005-09-29 2007-04-04 陆宪光 秋水仙碱及它的衍生物的医学用途
WO2007048004A2 (en) 2005-10-21 2007-04-26 Cornell Research Foundation, Inc. Compounds for enhancing hypoxia inducible factor activity and methods of use
EP2023874A4 (en) 2006-06-02 2009-07-08 Bioseek Inc METHOD FOR IDENTIFYING ACTIVE SUBSTANCES AND THEIR USE FOR THE PREVENTION OF RESTENOSIS
JP4743321B2 (ja) * 2006-06-09 2011-08-10 ウーツェーベー ファルマ ゲーエムベーハー フェソテロジンを含む安定した医薬組成物
PT103884A (pt) * 2006-11-17 2008-05-19 Astrazeneca Ab Composições de libertação prolongada e métodos para a sua preparação
WO2008131192A2 (en) 2007-04-18 2008-10-30 The Trustees Of Columbia University In The City Of New York Crystalline cholestrol and prevention of atherosclerosis
US20090093548A1 (en) 2007-10-05 2009-04-09 Mutual Pharmaceutical Company, Inc Colchine compositions and methods
CN101485637B (zh) * 2008-01-18 2011-03-30 普尔药物科技开发（深圳）有限公司 秋水仙碱骨架控释片或胶囊
CN101485638A (zh) * 2008-01-18 2009-07-22 普尔药物科技开发（深圳）有限公司 秋水仙碱双层渗透泵控释片及其制备方法
US20090299155A1 (en) 2008-01-30 2009-12-03 Dexcom, Inc. Continuous cardiac marker sensor system
CN101536990A (zh) * 2008-03-18 2009-09-23 普尔药物科技开发（深圳）有限公司 秋水仙碱胃漂浮缓释片及其制备方法
EP2262786A4 (en) 2008-04-15 2014-07-09 Takeda Pharmaceuticals Usa Inc COLCHICIN SOLIDS FORMAT, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THEIR USE
DE102008047910A1 (de) * 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
GB0819287D0 (en) 2008-10-22 2008-11-26 Univ Bradford Compounds
CN101732274A (zh) * 2008-11-19 2010-06-16 普尔药物科技开发（深圳）有限公司 秋水仙碱双层缓释片及其制备方法
US7820681B1 (en) 2009-01-14 2010-10-26 Mutual Pharmaceutical Company, Inc. Methods for concomitant administration of colchicine and a second active agent
WO2010103365A2 (en) 2009-03-09 2010-09-16 Council Of Scientific & Industrial Research Sustained release composition of therapeutic agent
US20110046228A1 (en) 2009-08-20 2011-02-24 Mutual Pharmaceutical Company, Inc. Methods for administration of colchicine with grapefruit juice
US20110046227A1 (en) 2009-08-21 2011-02-24 Mutual Pharmaceutical Company, Inc. Methods for concomitant administration of colchicine and a second active agent
EP3315124B1 (en) * 2009-11-13 2021-01-06 Astrazeneca AB Bilayer tablet formulations
EP2481411A1 (en) * 2011-01-27 2012-08-01 Ratiopharm GmbH Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
CN104602686A (zh) 2012-04-13 2015-05-06 西玛贝医药公司 利用卤芬酯或卤芬酸以及抗炎剂治疗痛风患者中高尿酸血症的方法
EA032515B1 (ru) 2012-11-02 2019-06-28 Марри Энд Пул Энтерпрайзес, Лтд. Лечение или профилактика сердечно-сосудистых явлений с использованием колхицина
US20160081936A1 (en) * 2013-04-16 2016-03-24 Murray And Poole Enterprises Limited Sustained-release formulations of colchicine and methods of using same
CN110148563A (zh) 2019-05-23 2019-08-20 武汉新芯集成电路制造有限公司 一种半导体器件及其制造方法

Also Published As

Publication number Publication date
US20160081936A1 (en) 2016-03-24
WO2014170755A3 (en) 2015-02-19
MY207496A (en) 2025-02-28
ZA201507723B (en) 2023-05-31
CL2015003072A1 (es) 2016-09-23
AU2024205185A1 (en) 2024-08-15
AU2020294268B2 (en) 2024-05-02
JP2016521270A (ja) 2016-07-21
JP6480420B2 (ja) 2019-03-13
AU2019201048A1 (en) 2019-03-07
MX2015014656A (es) 2016-03-01
US20230414521A1 (en) 2023-12-28
MX2020012310A (es) 2021-01-29
CA2909370A1 (en) 2014-10-23
AU2014255434A1 (en) 2015-11-05
EA037375B1 (ru) 2021-03-22
CN105307643A (zh) 2016-02-03
US20150094323A1 (en) 2015-04-02
MA38576A1 (fr) 2017-05-31
US20150094322A1 (en) 2015-04-02
WO2014170755A2 (en) 2014-10-23
KR20150143725A (ko) 2015-12-23
EA201501024A1 (ru) 2016-08-31
US10610488B2 (en) 2020-04-07
AU2014255434B2 (en) 2018-11-08
US10130585B2 (en) 2018-11-20
PT2986280T (pt) 2021-05-07
EP2986280B1 (en) 2021-03-17
BR112015026418A2 (pt) 2017-07-25
EP2986280A2 (en) 2016-02-24
MA38576B2 (fr) 2020-02-28
BR112015026418B1 (pt) 2022-10-04
SG11201508571WA (en) 2015-11-27
MY198452A (en) 2023-08-29
US20190054028A1 (en) 2019-02-21
AU2019201048B2 (en) 2021-01-28
US20200030240A1 (en) 2020-01-30
CA3255918A1 (en) 2025-10-30
MX377426B (es) 2025-03-10
US11648206B2 (en) 2023-05-16
AU2020294268A1 (en) 2021-01-28
US10105319B2 (en) 2018-10-23
KR102271048B1 (ko) 2021-06-30
SI2986280T1 (sl) 2021-08-31

Similar Documents

Publication Publication Date Title
PL2986280T3 (pl) Preparat kolchicyny w postaci o przedłużonym uwalnianiu i metody tworzenia takiego samego
NO2026015I1 (no) zuranolone and pharmaceutically acceptable salts thereof
NO2026003I1 (no) olezarsen and pharmaceutically acceptable salts thereof
NL301094I2 (nl) Avapritinib en farmaceutisch aanvaardbare zouten daarvan
IL245036B (en) Pesticidal compositions and related methods
CL2016001241A1 (es) Nuevos compuestos pesticidas y usos
EP2973234A4 (en) DENDRITICAL STRUCTURES AND LABELS
EP2995589A4 (en) Anode active material and method for manufacturing same
PL2943078T3 (pl) Sposoby wytwarzania i kompozycje produktów konsumpcyjnych
DK3003039T3 (da) Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
PL3091003T3 (pl) Pochodna 1,2‑naftochinonu i sposób jej przygotowania
EP3029339A4 (en) CONNECTION AND AIRCRAFT STRUCTURE
DK2956471T3 (da) Il-1beta-hæmmersammensætning og anvendelse deraf
IL243199A0 (en) Method for obtaining a plant extract and associated compositions
HRP20181536T1 (hr) Supstituirani piperidinil-tetrahidrokinolini i njihova uporaba kao antagonisti alfa-2c adrenoreceptora
EP2985503A4 (en) JUNCTION STRUCTURE AND ITS JUNCTION METHOD
EP3048883C0 (en) PESTICIDE COMPOSITION AND ASSOCIATED PROCESS
EP3041028A4 (en) LAMINATE AND APPLICATION THEREOF
TWI562414B (en) Magnetoresistive element and method of manufacturing the same
EP2996685A4 (en) FLUID PROCESSING COMPOSITIONS AND METHODS
EP2988262A4 (en) APPLICATION ACQUISITION AND SENDING DEVICE
FR3007291B1 (fr) Composition cicatrisante et utlisation
EP2992874A4 (en) LOCALLY APPLIED LIPOSOME AND APPLICATION THEREOF
PL3083648T3 (pl) Sposób farmaceutyczny i półprodukty
FI20120169L (fi) Pinnoitus- ja materiaalinvalmistusmenetelmä